GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (FRA:M55) » Definitions » Gross-Profit-to-Asset %

Macrogenics (FRA:M55) Gross-Profit-to-Asset % : 12.60% (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Macrogenics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Macrogenics's annualized Gross Profit for the quarter that ended in Mar. 2025 was €28.8 Mil. Macrogenics's average Total Assets over the quarter that ended in Mar. 2025 was €228.8 Mil. Therefore, Macrogenics's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 was 12.60%.


Macrogenics Gross-Profit-to-Asset % Historical Data

The historical data trend for Macrogenics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics Gross-Profit-to-Asset % Chart

Macrogenics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.12 21.25 47.96 16.68 49.63

Macrogenics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.24 14.27 184.52 19.15 12.60

Competitive Comparison of Macrogenics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Macrogenics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Macrogenics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Macrogenics's Gross-Profit-to-Asset % falls into.


;
;

Macrogenics Gross-Profit-to-Asset % Calculation

Macrogenics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=129.918/( (273.649+249.881)/ 2 )
=129.918/261.765
=49.63 %

Macrogenics's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=28.832/( (249.881+207.723)/ 2 )
=28.832/228.802
=12.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Macrogenics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Macrogenics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Macrogenics Business Description

Traded in Other Exchanges
Address
9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Macrogenics Headlines

No Headlines